# JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform

- Link: https://www.thailand-business-news.com/pr-news/jacc-clinical-electrophysiology-publishes-12-month-outcomes-from-field-medicals-first-in-human-field-pulse-trial-94-2-per-vein-pvi-durability-with-optimized-waveform
- Published: 2026-09-20T21:53:00+07:00
- Author: PR Newswire

|   |

Late-breaking HRX data advance Field Medical’s "instantaneous ablation" workflow
and expand the clinical evidence for high-voltage focal PFA with the FieldForce™
PFA System

ATLANTA and CARLSBAD, Calif., Sept. 20, 2026 /PRNewswire/ — [**Field Medical, Inc.**](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778300-1&h=573299443&u=https%3A%2F%2Fwww.fieldmedicalinc.com%2F&a=Field+Medical%2C+Inc.)**,**
advancing high-voltage focal pulsed field ablation (PFA) for complex arrhythmias,
today announced publication of 12-month results from the first-in-human Field PULSE
trial in [_JACC: Clinical Electrophysiology_](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778300-1&h=1700319124&u=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS2405500X26008571&a=JACC%3A+Clinical+Electrophysiology).
The findings were presented simultaneously as a Late-Breaking Clinical Trial at 
HRX Live 2026.

[[

Field Medical developed the FieldForce™ PFA System around a high-voltage focal PFA
architecture designed first for the ventricle, where depth, stability and control
are among the most difficult challenges in ablation. Field PULSE extends that work
into the atrium and evaluates a subsecond point-by-point workflow Field Medical 
terms "instantaneous ablation." In this study, the approach was associated with 
procedural efficiency, durable pulmonary vein isolation (PVI) and flexibility beyond
the pulmonary veins, without the need for prolonged catheter stability.

**Key Findings:**

 ◦ **Procedural efficiency with subsecond focal PFA:** 13-minute median elapsed 
   PVI ablation time, with a fastest time of 7.7 minutes
 ◦ **Durable PVI with the optimized waveform:** 94.2% per-vein durability reflecting
   progressive improvement with waveform evolution
 ◦ **Flexible focal ablation:** 49% of patients received non-PV ablation for additional
   atrial targets
 ◦ No primary safety events were observed
 ◦ 80% freedom from atrial arrhythmias at 12 months with the optimized waveform

"Field PULSE demonstrates the feasibility of truly instantaneous focal PFA," said
Vivek Reddy, M.D., co-principal investigator, lead author and electrophysiologist
at Mount Sinai Health System. "Delivering the full application in less than 200 
milliseconds reduces the need for prolonged catheter stability while preserving 
the flexibility of point-by-point ablation. The procedural efficiency, safety and
pulmonary vein durability observed with the optimized waveform support continued
clinical development of this approach."

The publication builds on Field Medical’s peer-reviewed clinical work in ventricular
tachycardia. Six-month outcomes from the company’s first-in-human VCAS trial were
published in _Circulation_ in 2025. Field PULSE now adds first-in-human, peer-reviewed
atrial data evaluating the same high-voltage focal PFA architecture through a distinct
focal workflow in a different cardiac substrate.

"We designed FieldForce to solve some of the hardest problems in focal cardiac ablation,
beginning in the ventricle," said Mark A. Turco, M.D., president and chief executive
officer of Field Medical. "Field PULSE demonstrates that the same high-voltage focal
PFA architecture can support an ‘instantaneous ablation’ workflow in the atrium.
This growing body of evidence reinforces the range of the platform: depth and focal
control in the ventricle, speed and precision in the atrium, and the versatility
to address very different cardiac substrates through a familiar point-by-point approach.
These results add important clinical evidence as we continue to advance our differentiated
PFA platform."

The study, "[High-Voltage Focal PFA Catheter for ‘Instant’ Point-By-Point Ablation: The First-In-Human FIELD-PULSE Trial to Treat AF](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778300-1&h=1463604268&u=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS2405500X26008571&a=High-Voltage+Focal+PFA+Catheter+for+%27Instant%27+Point-By-Point+Ablation%3A+The+First-In-Human+FIELD-PULSE+Trial+to+Treat+AF),"
was published online in_ JACC: Clinical Electrophysiology_ concurrent with the HRX
presentation. DOI: 10.1016/j.jacep.2026.09.001.

**About Field Medical®, Inc.**
Field Medical is a clinical-stage medical technology
company committed to advancing pulsed field ablation (PFA) solutions for complex
cardiac arrhythmias. The company was founded by Steven Mickelsen, M.D., CTO, a pioneer
and global thought leader in PFA whose work has helped shape the evolution of the
field. The FieldForce PFA System integrates a focal catheter design with proprietary
FieldBending™ energy designed to safely deliver efficient, precise ablation with
the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In
2024, Field Medical earned Breakthrough Device Designation and gained entry into
the [FDA TAP Pilot Program](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778300-1&h=2524247871&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4640991-1%26h%3D1947131265%26u%3Dhttps%253A%252F%252Fwww.prnewswire.com%252Fnews-releases%252Ffield-medicals-fieldforce-ablation-system-earns-fda-tap-pilot-acceptance-and-breakthrough-device-designation-for-the-treatment-of-ventricular-tachycardia-302323593.html%26a%3DFDA%2BTAP%2BPilot%2BProgram&a=FDA+TAP+Pilot+Program)
for its ventricular tachycardia indication. In October 2025, the VCAS trial was 
published in [_Circulation_](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778300-1&h=425409823&u=https%3A%2F%2Fwww.ahajournals.org%2Fdoi%2F10.1161%2FCIRCULATIONAHA.125.077025&a=Circulation).

For more information, visit [fieldmedicalinc.com ](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778300-1&h=59219360&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4640991-1%26h%3D395418203%26u%3Dhttp%253A%252F%252Fwww.fieldmedicalinc.com%252F%26a%3Dwww.fieldmedicalinc.com&a=fieldmedicalinc.com%C2%A0)
and follow us on [LinkedIn](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778300-1&h=3593370244&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4640991-1%26h%3D2749833079%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Ffield-medical%26a%3DLinkedIn&a=LinkedIn)
and [YouTube](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4778300-1&h=723051108&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4640991-1%26h%3D2092504710%26u%3Dhttps%253A%252F%252Fwww.youtube.com%252F%2540FieldMedical%26a%3DYouTube&a=YouTube).

The FieldForce™ PFA System is an investigational device and is limited by federal(
or United States) law to investigational use.

**Media Contact**
Holly Windler619.929.1275[media@fieldmedicalinc.com](https://www.thailand-business-news.com/pr-news/media@fieldmedicalinc.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform ](http://www.prnasia.com/story/archive/5052097_AE52097_0?rand=184833)